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Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolled in the ALS Multicenter
Cohort Study of Oxidative Stress (ALS COSMOS). Methods. We analyzed data from 294 ALS participants, 134 of whom were
studied serially. Change over time was evaluated controlling for age, sex, symptom duration, education, race, and ethnicity.
Using multiple regression, we evaluated associations among decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores,
forced vital capacity (FVC), and cognitive/behavioral changes. Change in cognitive/behavioral subgroups was assessed using
one-way analyses of covariance. Results. Participants with follow-up data had fewer baseline behavior problems compared to
patients without follow-up data. We found significant worsening of behavior (ALS Cognitive Behavioral Screen (ALS CBS)
behavioral scale, p < 0 001; Frontal Behavioral Inventory-ALS (FBI-ALS) disinhibition subscale, p = 0 044). Item analysis
suggested change in frustration tolerance, insight, mental rigidity, and interests (p < 0 05). Changes in ALSFRS-R correlated with
the ALS CBS. Worsening disinhibition (FBI-ALS) did not correlate with ALSFRS-R, FVC, or disease duration. Conclusion. We
Hindawi
Behavioural Neurology
Volume 2018, Article ID 5969137, 7 pages
https://doi.org/10.1155/2018/5969137
did not detect cognitive change. Behavioral change was detected, and increased disinhibition was found among patients with
abnormal baseline behavioral scores. Disinhibition changes did not correlate with disease duration or progression. Baseline
behavioral problems were associated with advanced, rapidly progressive disease and study attrition.
1. Introduction
Patients with ALS may exhibit cognitive deficits, ranging
from mild executive or language dysfunction to severe
deficits consistent with dementia. For others, cognition may
be relatively preserved yet behavioral symptoms are present,
ranging from mild apathy to severe behavioral dysfunction
reflecting frontotemporal dementia (FTD). ALS patients
may demonstrate cognitive and behavioral deficits simulta-
neously, and those with marked deficits in both domains
typically suffer from ALS-FTD.
ALS patients with concomitant FTD have shorter
survival [1]. Nondemented patients with mild-moderate
cognitive or behavioral abnormalities are also impacted prog-
nostically. Patients who present with any degree of executive
dysfunction at the time of diagnosis are more likely to exhibit
faster cognitive and motor progression [2]. ALS patients who
are cognitively normal at baseline are more likely to remain
cognitively unchanged over time. Behavioral changes may
predate both motor and cognitive symptoms in ALS [3],
although less is known about longitudinal behavioral change
in nondemented ALS patients. The recent study [4] found
that severe apathy is a significant negative prognostic indica-
tor in ALS regardless of severity of physical disease.
We previously reported that among participants enrolled
in ALS COSMOS, rates of cognitive and behavioral impair-
ment were consistent with existing literature, which supports
the utility of cognitive and behavioral screening tools in large
trials [5]. Here, we report on longitudinal data from the ALS
COSMOS study in order to describe the natural history of
both cognition and behavior in ALS.
2. Materials and Methods
2.1. Participant Selection and Consent. The ALS COSMOS
study is a large, prospective, multicenter, interdisciplinary,
epidemiological study of oxidative stress which has been
described previously [6]. Two hundred ninety-four partici-
pants were enrolled at baseline. Current data is based on
134 participants with both baseline and follow-up assess-
ments. The mean time interval between assessments was
11.5± 2.4 months.
IRB approval was obtained at each clinical site. Written
informed consent was provided by all participants and
their caregivers.
2.2. Cognitive and Behavioral Screening. Participants
repeated a number of neuropsychological screens of cogni-
tive and behavioral functioning. The ALS Cognitive Behav-
ioral Screen (ALS-CBS) [7], the Verbal Fluency Index C
words (VFI) [8], and Controlled Oral Word Association Test
(COWAT) [9] were used to assess executive functioning,
attention, verbal fluency, and mental control. The behavioral
scale of the ALS CBS was used to evaluate for changes
in personality, social comportment, and apathy based
on caregiver’s report. The Frontal Behavioral Inventory-
ALS (FBI-ALS) version [10] was also used, which is an
interview-based tool. The FBI-ALS is comprised of the
negative scale (measures apathy, emotional flatness, and
aspontaneity) and the disinhibition scale (measures behav-
iors like inappropriateness, impulsivity, and hyperorality).
The Center for Neurological Study-Lability Scale (CNS-LS)
[11], completed by the patient, is a screening tool for pseu-
dobulbar affect (PBA). For further explanation of study
measures, please refer to the baseline study [5].
2.3. Clinical and Demographic Variables. Functional disabil-
ity was measured using the ALS Functional Rating Scale-
Revised (ALS FRS-R) [12], and ventilatory status was
measured using forced vital capacity (FVC). Duration of
symptoms prior to diagnosis, time since diagnosis, and site
of onset were recorded. Illness onset was defined as the first
sign of muscle weakness and/or symptoms caused by muscle
weakness [13]. Fasciculations, cramps, and fatigue were not
considered signs of illness onset. The MMSE (Mini-Mental
State Examination) [14] was administered at baseline but
not at follow-up. Demographic variables included age, gen-
der, education, and ethnicity. All data were stored in the Data
Management Center at the Columbia University Medical
Center [6].
2.4. Statistics. Statistical analyses were conducted using
SPSS version 23.0 and SAS version 9.4. We identified a
set of covariates that were associated with baseline ALS
functional measures for all analyses: age, sex, duration of
symptoms, education, race, and ethnicity. Analysis of
covariance (ANCOVA) procedures were used to compare
demographic and illness characteristics of cases with only
baseline assessments versus cases with baseline and follow-
up data. Visual inspection of histograms and Kolmogorov-
Smirnov tests were used to assess the normality assumption
of ANCOVA.
Follow-up cognitive assessments were performed 5–18
months after baseline (mean: 11.5 months). We calculated
the time between the two assessments and categorized this
time into quartiles. We examined all cognitive and behavioral
measures by these quartiles and found no differences.
Because there were no differences in cognitive and behavioral
change related to the time between assessments, all cases
were subsequently examined together.
Generalized estimating equations (GEE) were used to
evaluate change over time for all measures, controlling for
the a priori covariates. Multiple regression analysis was
conducted to further examine changes over time. Change
scores were calculated for cognitive, behavioral, and disease
progression measures by comparing baseline scores to scores
at follow-up. Negative change score values indicate a worsen-
ing of condition from baseline to 12-month follow-up.
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Change scores served as the dependent variable, while inde-
pendent variables included the a priori covariates and the
baseline score. Because the ALS CBS behavioral scores
differed significantly from baseline to follow-up (decrement
in function), we performed an item analysis of this scale first
looking at the unadjusted changes in responses, then using
general linear models, and controlling for covariates.
Using diagnostic criteria established by Strong et al. [15],
we created diagnostic subgroups (normal, mild impairment,
and moderate impairment) using the baseline ALS CBS
cognition score, the baseline Verbal Fluency Index (normal
and impaired) and the baseline ALS CBS behavioral score.
Change scores were calculated for each diagnostic subgroup
on each measure to examine the longitudinal progression of
patients based on these classifications. We then performed
a one-way ANCOVA to examine change scores across each
diagnostic subgroup to determine whether baseline cogni-
tive/behavioral diagnostic classification is associated with
the degree of cognitive or behavioral change, if any. When
significant differences were detected between diagnostic
groups, we ran post hoc pairwise comparisons to determine
specifically which groups differed from each other.
All tests were two-tailed, and significance was set at
p < 0 05 for analyses. We performed sensitivity analyses
using Bonferroni-corrected alpha levels to control for
multiple comparisons.
3. Results
3.1. Comparison of Cases with and without Cognitive/
Behavioral Follow-Up Data. Cases with follow-up cognitive/
behavioral test scores had higher baseline ALSFRS-R
(p < 0 001) and FVC (p < 0 001) ratings (Table 1), compared
to cases without follow-up data. Cases in the follow-up group
also had longer disease durations at baseline (p = 0 012) and
were two years younger than those without follow-up
(p = 0 047), although this age difference was no longer
significant after Bonferroni correction. Other demographic
variables did not differ significantly between groups.
Further, cases with follow-up data had significantly
higher scores (reflecting fewer behavior problems) on
the baseline ALS-CBS behavioral scale total compared
to cases with no follow-up data (p = 0 036). No differ-
ences were found between cases with and without
follow-up data on the other cognitive and behavioral
tests (Table 1).
3.2. Cognitive Impairment at Follow-Up. Based on the ALS
CBS cognitive score at follow-up, 5.2% of participants were
classified in the range consistent with dementia and 54% in
the mild cognitive impairment range (ALSci). This is consis-
tent with baseline rates of impairment from the larger cohort
(6.5% and 54.2%, respectively) [5]. Using the Verbal Fluency
Index, 43.4% of the participants scored in the mildly
impaired range at follow-up.
The cognitive screening tools (ALS CBS cognitive scale
and VFI) did not reveal significant change during the
follow-up period (Table 2). Although the sample means on
the ALS CBS cognitive scale did not change over time (15.6
versus 15.4), regression analysis revealed that greater decline
in performance was associated with being male (p = 0 034),
longer duration between assessments (p = 0 033), and higher
Table 1: Comparative analysis of baseline data for two groups: 134 cases with follow-up data compared to 160 cases without follow-up data.
Variable
Participants completing baseline and
follow-up assessments (mean/SD)
N
Participants completing baseline
assessment only (mean/SD)
N p
Age 59.7 (10.1) 134 61.8 (9.9) 160 0.076
Onset to baseline assessment 14.3 (4.9) 134 12.8 (4.9) 160 0.012
Time from illness to enrollment 12.6 (4.4) 134 11.1 (4.3) 160 0.005
ALSFRS-R 38.5 (5.0) 129 34.2 (7.1) 154 <0.001
FVC 86.6 (20.5) 129 73.3 (22.4) 140 <0.001
% male 59.3 134 59 160 0.958
Race, % white 88.2 134 91.0 160 0.427
Hispanic ethnicity 9.3 134 4.5 160 0.108
Education 134 160
% HS/GED 26.7% 20.9%
Some college, AA 34.8% 29.1%
BA, BS, or higher 38.5% 50.0% 0.138
MMSE 29.1 (1.4) 120 28.8 (2.0) 132 0.121
CBS cognitive score 15.6 (2.8) 120 15.1 (3.3) 134 0.126
CBS behavioral score 37.4 (5.2) 118 34.7 (6.9) 131 0.036
FBI negative scale 3.2 (4.9) 119 4.0 (4.7) 132 0.119
FBI disinhibition scale 1.45 (2.56) 119 1.87 (2.31) 132 0.127
CNS-Lability Scale 12.2 (4.5) 130 13.7 (5.4) 158 0.009
COWAT total 36.7 (10.7) 64 33.3 (11.6) 80 0.076
VFI C words 13.8 (7.7) 77 11.3 (6.9) 52 0.177
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baseline CBS scores (p < 0 001). For sensitivity, we compared
these p values to the Bonferroni-corrected alpha level of
0.005, for the 10 variables in the model. Higher baseline
CBS scores persisted as a significant predictor of ALS CBS
cognitive scale change using this conservative method. VFI
decline was significantly associated with greater disease
progression, as assessed by ALSFRS-R (p = 0 010), although
fewer participants completed this screen at follow-up. The
ALS CBS cognitive scale and COWAT did not associate with
ALSFRS-R scores.
3.3. Behavioral Impairment at Follow-Up. Using ALS CBS
behavioral cutoff scores [3], 14.9% of the sample scored
within the range that suggests dementia at follow-up. This
is equivalent with the percentage of patients in the baseline
cohort with probable dementia at baseline (16.5%) [5].
Approximately 11.2% of participants scored within the
range of mild behavioral impairment (ALSbi) at follow-up,
comparable to 14.1% who were mildly impaired at baseline.
The ALS CBS behavioral total (p < 0 001) and the FBI-
ALS disinhibition scale (p = 0 044) changed significantly
during the follow-up period, suggesting behavioral deteriora-
tion, although the change in FBI-ALS disinhibition scale is no
longer significant after Bonferroni correction (Table 2).
Regression analysis showed that the decline in CBS behavior
score was associated with disease progression (ALSFRS-R,
p = 0 001). FBI disinhibition scores were not associated with
any of the independent variables. The FBI-ALS negative scale
remained stable from baseline to follow-up. Although the
CNS-Lability Scale (CNS-LS) remained stable from baseline
to follow-up, change on this measure was associated with dis-
ease progression (ALSFRS-R, p = 0 006 and FVC, p = 0 040)
and the CNS-LS baseline score (p = 0 001).
We examined each item of the ALS CBS behavioral
scale for change during follow-up. Without controlling for
covariates, specific item scores that changed across the
interval, reflecting deterioration in behavior, included the
following: decreased interest in topics/events that used to be
important, decreased ability to deal with frustration or stress,
difficulty changing opinions/adapting to new situations, and
decreased awareness of obvious problems/changes or denial.
After adjusting for the same a priori covariates, all of these
items except for “decreased interest in topics/events that used
to be important,” were significantly different with p < 0 0001.
3.4. Change across Diagnostic Subgroups. Participants were
classified into diagnostic subgroups (no impairment, mild
impairment, and suspected dementia) according to consen-
sus criteria [15] based on baseline ALS CBS scores. The
ALS CBS cognitive change score differed among the three
cognitive diagnostic subgroups (Table 3, p=<0.001). Partici-
pants in the no impairment and mild cognitive impairment
subgroups had relatively stable cognitive scores between
baseline and follow-up. Surprisingly, the dementia subgroup
showed improvement on the CBS cognitive total (Table 3).
No changes on other cognitive measures were found among
baseline diagnostic subgroups.
Similar analyses were completed across behavioral diag-
nostic subgroups based on the baseline ALS CBS behavioral
score. We detected significant decline (p = 0 008) between
baseline and follow-up on the FBI disinhibition scale for all
three behavioral diagnostic subgroups (Table 4). The greatest
decline in disinhibition was found among participants
classified in the dementia subgroup at baseline compared to
the nonimpaired and participants with mild behavioral
impairment (p = 0 002 and 0.056, respectively).
There were 6 cases identified as normal at baseline who
transitioned to dementia at follow-up, exhibiting an expected
and significant decline in behavioral scores (p = 0 002). How-
ever, these specific cases did not demonstrate an equivalent
decline in ALS CBS cognitive scores (p = 0 320).
3.5. Site of ALS Onset. We examined all of the change scores
with respect to the site of ALS onset (bulbar versus spinal),
controlling for the a priori covariates. Bulbar-onset partici-
pants exhibited a greater decline in VFI (p = 0 013) compared
to spinal-onset participants. No other change was evident.
4. Discussion
Significant behavioral change occurs in ALS patients over
time, as indicated on screening measures completed by
caregivers, including the FBI-ALS and ALS CBS. Behavioral
change was not associated with disease duration or
Table 2: Change over time: comparison of baseline and follow-up scores in 134 participants with longitudinal data, using GLM-GEE
procedures, controlling for age, sex, duration of symptoms, education, race, and ethnicity (adjusted means and standard errors).
Baseline mean (SE) Follow-up mean (SE)
Fixed effects for interval
Wald chi-square value p value
ALSFRS 38.5 (39.1) 27.6 (39.1) 240.27 <0.001⊥
FVC% 86.7 (95.0) 64.5 (94.7) 114.13 <0.001⊥
ALS CBS cognitive score 15.6 (9.8) 15.4 (9.8) 0.82 0.450
ALS CBS behavioral score 37.5 (31.0) 35.5∗ (30.9) 15.16 <0.001⊥
Verbal Fluency Index (z-score converted) −0.159 (3.79) 0.063∗∗ (3.74) 1.51 0.252
FBI negative scale 3.2 (20.3) 4.1 (20.2) 2.63 0.090
FBI disinhibition 1.46 (13.3) 2.01 (13.2) 4.07 0.044
CNS lability score 12.2 (20.2) 11.9∗∗∗ (20.2) 0.78 0.378
∗Decline in CBS behavioral score correlates with ALSFRS-R (p = 0 001). ∗∗Decline in VFI score correlates with ALSFRS-R (p = 0 010). ∗∗∗Decline in CNS-LS
score correlates with ALSFRS-R (p = 0 006) and FVC (p = 0 040). ⊥Significant at the Bonferroni-adjusted alpha level of 0.007.
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respiratory decline, but changes detected with the ALS CBS
were associated with functional disability (ALSFRS-R scores).
In contrast, disinhibition measured by the FBI-ALS was not
associated with any disease severity indices.
Participants with behavioral problems consistent with
FTD at baseline demonstrated more rapid progression of
behavioral disinhibition over time compared to behaviorally
normal participants or those with mild behavioral abnormal-
ities. Despite the high prevalence of apathy in ALS [16, 17],
significant change in this behavioral symptom was not
detected using the FBI negative scale. However, an item
analysis of the ALS CBS suggested progression of apathy,
identified by change on an item measuring interest in topics
and activities. Other behavioral symptoms that changed sig-
nificantly over time included reduced frustration tolerance,
reduced adaptability to new situations/changing opinions,
and decreased insight. These results contribute to the existing
literature that suggests that subtle behavioral changes are
pervasive in ALS [3] and may be seen in patients without a
clinically obvious syndrome [18].
Behavioral data was obtained from caregivers via a
written questionnaire (ALS CBS) and interview (FBI-ALS).
Caregiver perspectives can be biased by factors such as
disease severity, mood, and psychosocial stress, which may
lead to measurement error. The recent study found that
behavioral impairment, but not cognitive impairment,
negatively impacted caregiver burden in ALS [19]. Future
behavioral studies may be strengthened by controlling for
caregiver burden and caregiver depression/anxiety [20],
which may provide an alternative explanation for increased
rates of reported behavioral abnormalities over time and
correlation with functional disability.
Using ALS CBS behavioral score cutoffs [7], nearly
15% of the sample fell within the range suggestive of
FTD at follow-up. When FTD was estimated based on
cognition rather than behavior, the rate was only 5.2%. It
is possible that the rate discrepancy reflects the behavioral
basis of FTD, since initial FTD symptoms frequently include
social deficits or personality change rather than overt prob-
lems with concentration, set shifting, or fluency. Cognitive
screening, if used without behavioral data, may underesti-
mate the rate of dementia in ALS research cohorts.
Cognitive decline was not detected in this study. Study
attrition correlates with cognitive impairment in ALS [2],
and longitudinal studies may be enriched with cognitively
intact patients [2]. Our results did not replicate this
Table 4: Change in scores over time across diagnostic groups, defined by baseline ALS-CBS behavioral scores, controlling for age, sex, time
from illness onset to baseline testing, and time between assessments (GLM ANCOVA, adjusted means, and standard errors are presented).
Cognitive and behavioral screens
Change scores across diagnostic subgroups (behavioral)∗
ANCOVA Pairwise
1
Normal
2
Mild
3
Moderate
N = 86 – 93 N = 10 – 11 N = 13 – 16
MN SE MN SE MN SE F p p < 0 050
ALS-CBS cognition −0.23 0.313 −0.31 0.917 0.46 0.823 0.32 0.729 None
ALS-CBS behavior −2.21 0.60 −3.00 1.71 −0.26 1.47 0.93 0.400 None
FBI negative −0.79 0.59 −0.17 1.71 −1.96 1.52 0.35 0.708 None
FBI disinhibition −0.37 0.274 −0.76 0.793 −2.80 0.706 5.01 0.008∗⊥ 1 vs. 3
CNS-Lability Scale 0.46 0.42 −0.55 1.18 −0.22 1.02 0.45 0.640 None
∗Diagnostic subgroups were determined based on baseline ALS CBS scores on the behavioral screen [7]. Normal: no significant behavioral impairment; mild:
suspicion of mild behavioral impairment; moderate: suspicion of moderate-severe behavioral impairment, raising suspicion for dementia. ⊥Significant at
Bonferroni-adjusted alpha level of 0.01.
Table 3: Change in scores over time across diagnostic groups, defined by baseline ALS-CBS cognitive scores, controlling for age, sex, time
from illness onset to baseline testing, and time between assessments (GLM ANCOVA, adjusted means, and standard errors are presented).
Cognitive and behavioral screens
Change scores across diagnostic subgroups (cognitive)∗
ANCOVA Pairwise
1
Normal
2
Mild
3
Moderate
N = 48 – 49 N = 60 – 62 N = 7 – 9
MN SE MN SE MN SE F p p < 0 05
ALS-CBS cognition −1.12 0.373 0.13 0.335 4.33 0.983 13.92 0.001∗⊥ All
ALS-CBS behavior −1.21 0.820 −2.50 0.730 −3.12 1.88 0.85 0.430 None
FBI negative −0.89 0.82 −0.92 0.73 −.61 1.90 0.01 0.989 None
FBI disinhibition −0.32 0.39 −0.77 0.35 −2.48 0.90 2.45 0.091 1 vs. 3
CNS-Lability Scale −0.27 0.56 0.66 0.50 0.67 1.30 0.78 0.460 None
∗Diagnostic subgroups were determined based on baseline ALS CBS scores on the cognitive screen [7]. Normal: no significant cognitive impairment;
mild: suspicion of mild cognitive impairment; moderate: suspicion of moderate-severe cognitive impairment, raising suspicion for dementia. ⊥Significant at
the Bonferroni-adjusted alpha level of 0.01.
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association, but we did detect an association between behav-
ioral impairment and attrition. Participants who did not
remain in the study were older and had more advanced dis-
ease that progressed more rapidly. These participants also
had more baseline behavioral problems, suggesting an associ-
ation between behavioral symptoms and more aggressive
motor disease. Caga et al. [4] studied apathy and found that
participants with the most severe behavioral impairment
have significantly shorter mean survival (22 months) com-
pared to those with mild apathy (46.9 months) or those with-
out apathy (52 months).
Analysis of the baseline data from this cohort [5] sug-
gested a significant correlation between apathy and cognitive
impairment. These data also suggested a correlation between
the absence of cognitive impairment and the presence of
behavioral disinhibition. When considered within the con-
text of attrition and longitudinal follow-up, the behavioral
data makes sense. If longitudinal trials enrich for cognitively
intact participants [2], then we may expect to see more
disinhibition over time since it correlates with a relative lack
of cognitive impairment. In contrast, since apathy correlated
with cognitive impairment at baseline, we do not see marked
increases in apathy over time because cognitively impaired
patients may have a greater risk of attrition. These data
suggest the possibility of two distinct phenotypes for further
study: (1) patients with mild cognitive impairment and apa-
thy and (2) cognitively normal patients with disinhibition.
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